Innovations in excipients are crucial for the pharmaceutical industry, especially as regulatory scrutiny intensifies. Nigel Langley, the Global Technical Director of Life Sciences at gChem, recently highlighted these issues during a presentation at CPHI Frankfurt 2025. His insights shed light on significant challenges in excipient availability, the impact of regulatory shifts, and the urgent need for novel excipient innovation.
Excipient Innovations at CPHI 2025
At CPHI 2025, gChem is showcasing its flagship product, Procipient, a high-purity pharmaceutical-grade dimethyl sulfoxide (DMSO). Procipient serves dual roles as both an active pharmaceutical ingredient (API) and an excipient, supported by comprehensive Drug Master Files in the US and Canada. Additionally, gChem is promoting two other grades of DMSO: Synthesis grade, aimed at API and peptide synthesis, and ACS grade, which is intended for laboratory analytical applications.
Regulatory Pressures on Traditional Excipients
Currently, the pharmaceutical industry faces significant regulatory challenges, particularly concerning traditional excipients like titanium dioxide (TiO2). Heightened scrutiny stems from safety concerns linked to various impurities, including nitrosamines, microplastics, and per- and polyfluoroalkyl substances (PFAS). These regulatory pressures originate from both European and US jurisdictions and pose risks to the availability of essential excipients. For instance, a proposed ban on TiO2 could have necessitated the reformulation of approximately 90,000 drug products in Europe, a scenario that could have resulted in severe drug shortages.
Anticipating Regulatory Changes
Pharmaceutical companies must adopt proactive strategies to navigate the complex regulatory landscape. The challenge lies in anticipating which regulatory focus will emerge next. Ideally, sound scientific evidence should guide these decisions, yet recent trends indicate that isolated studies sometimes drive regulatory actions, potentially misrepresenting broader scientific understanding.
A notable example of effective industry response occurred with the TiO2 situation. When European regulations threatened to ban this excipient, the pharmaceutical sector rallied to present robust scientific arguments defending its safety. This proactive approach ultimately contributed to a more informed decision-making process.
Strengthening Supply Chain Resilience
Pharmaceutical firms must address the risks associated with single sourcing for raw materials, including excipients. To mitigate potential disruptions, companies should explore diverse sourcing options, such as manufacturing at multiple global sites or maintaining safety stock in various locations.
Sustainability also plays a critical role in this discussion. DMSO, classified as a Class 3 solvent, presents a greener alternative to more toxic Class 2 solvents currently used in drug synthesis. As the industry moves towards more sustainable practices, the adoption of safer solvents can improve both environmental impact and patient outcomes.
Integrating Sustainable Practices
Companies are increasingly evaluating the carbon footprint associated with excipient production and raw materials sourcing. Effective communication with suppliers is essential for understanding the origins of raw materials and manufacturing processes.
The shift towards safer solvents is another key avenue for enhancing sustainability. Chemicals like dichloromethane and dimethylformamide, which are facing bans, exemplify the need for sustainable alternatives. Utilizing safer solvents not only aligns with regulatory trends but also supports long-term sustainability goals.
Accelerating Novel Excipient Development
The need for novel excipients has never been more pressing, yet significant barriers hinder their introduction. The pharmaceutical industry often relies on older excipients that may not meet the demands of increasingly complex drug formulations.
Innovative excipients are essential for advancing new drug modalities. The FDA’s Prime process, introduced three years ago, aimed to streamline the review of new chemical entities as excipients. However, the future of this initiative remains uncertain, with concerns that it may be stalled.
To drive innovation, closer collaboration between pharmaceutical companies and excipient suppliers is necessary. Suppliers should be viewed as strategic partners rather than mere vendors, fostering early dialogue about formulation needs and challenges.
The Role of Academia in Excipient Innovation
Academia holds a pivotal role in the development of new chemical entities for drug formulation. However, translating research into commercial applications poses challenges. New excipients must pass rigorous safety evaluations before being adopted.
Pharmaceutical companies often exhibit caution, waiting for successful implementations by others before committing to novel excipients. This cautious approach stems from perceived risks associated with introducing new materials into drug formulations. Enhanced collaboration between academia and industry can help mitigate these risks.
Conclusion
The pharmaceutical landscape is evolving, and excipient innovation plays a critical role in ensuring the industry’s future viability. By embracing proactive strategies, fostering collaborations, and prioritizing sustainability, companies can navigate the complex regulatory environment while addressing the urgent need for innovative excipients. The path forward demands both adaptability and a commitment to scientific integrity, ensuring that patient safety and drug efficacy remain paramount.
- Understanding regulatory trends is essential for anticipating challenges.
- Collaboration between pharma companies and excipient suppliers can drive innovation.
- Sustainable practices are increasingly important in excipient production.
- Embracing novel excipients will be key to addressing the complexities of modern drug formulations.
- Proactive strategies can mitigate risks associated with supply chain disruptions.
Source: www.pharmtech.com